Fig. 7: MAPK4 inhibits the activation of the PI3K signaling pathway in B cells of arthritis mice by activating the IRF4-SHIP1 pathway.

A Western blot analysis of pSHIP1 and pIRF4 expression levels in B cells from WT and MAPK4 KO mice stimulated in vitro with sAg for 0, 5, 10, and 30 min. B Western blot analysis of SHIP1 expression in B cells from WT and MAPK4 KO mice. C Co-immunoprecipitation assay to analyze the interaction between IRF4 and MAPK4. D Western blot analysis of pIRF4, pSHIP1, pPI3K (p85), and pAKT expression levels in WT B cells stimulated in vitro with sAg for 0, 5, 10, and 30 min, with or without Vacquinol-1 treatment. Representative blots from three independent experiments are presented for all of the above. E–H Flow cytometry (E-G) and statistical (H) analysis of FO(E), T1(E), T2(E), MZ(F), and GC (G) B cell subpopulations in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). I–K Flow cytometry (I) and statistical analysis (J-K) of CD4 and CD8 T cells from the spleen and thymus in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). L, M Flow cytometric analysis of IL-10 and IL-6 expression levels in B cells from WT, CIA, and CIA mice treated in vitro with Vacquinol-1 for 1 h (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001.